Wells Fargo
BCAB icon

Wells Fargo’s BioAtla BCAB Stock Holding History

Wells Fargo’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-312
Closed -$53.6K – 6924
2024
Q1 		$53.6K Buy
312
+40
+15% +$4.97K ﹤0.01% 5233
2023
Q4 		$33.4K Buy
272
+54
+25% +$4.68K ﹤0.01% 5429
2023
Q3 		$18.5K Sell
218
-119
-35% -$15.2K ﹤0.01% 5630
2023
Q2 		$50.6K Buy
337
+331
+5,517% +$56.9K ﹤0.01% 5425
2023
Q1 		$844 Hold
6
– – ﹤0.01% 6429
2022
Q4 		$2.57K Buy
6
+1
+20% +$415 ﹤0.01% 5950
2022
Q3 		$1K Buy
5
+1
+25% +$327 ﹤0.01% 6274
2022
Q2 		$0 Sell
4
-2
-33% -$318 ﹤0.01% 6793
2022
Q1 		$1K Sell
6
-110
-95% -$46K ﹤0.01% 6753
2021
Q4 		$114K Buy
116
+115
+11,500% +$147K ﹤0.01% 5564
2021
Q3 		$1K Hold
1
– – ﹤0.01% 6655
2021
Q2 		$2K Sell
1
-71
-99% -$160K ﹤0.01% 6523
2021
Q1 		$184K Buy
+72
New +$185K ﹤0.01% 5192

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
SAM
Scion Asset Management Saratoga, California $1.38B AUM 43.96% 1-Year Est. Return

Wells Fargo's BCAB Position: Q2 2024 in Review

Wells Fargo sold out of BioAtla (BCAB) in Q2 2024, closing a stake of 312 shares — an estimated $53.6K sold.

Wells Fargo first reported a position in BCAB in Q1 2021 and held it in 13 quarters. The position peaked at $184K in Q1 2021. 80 funds tracked by Wall St. Rank hold BCAB as of Q2 2024.

  • Wells Fargo reported no remaining BioAtla position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 312 BioAtla shares in Q2 2024, an estimated $53.6K.
  • Wells Fargo first reported a position in BioAtla in Q1 2021 and held it in 13 quarters.
  • Wells Fargo's BioAtla position peaked at $184K in Q1 2021.
  • 80 funds tracked by Wall St. Rank held BioAtla as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.